by TractManager | Aug 30, 2019 | News
The Food and Drug Administration (FDA) has issued a safety communication to manufacturers and healthcare facilities to begin transitioning to duodenoscopes with disposable components to reduce risk of patient infection. This update was issued to provide the latest...
by TractManager | Aug 29, 2019 | News
The Food and Drug Administration (FDA) has received reports that the use of Mavyret (glecaprevir and pibrentasvir; Abbvie Inc.), Zepatier (elbasvir and grazoprevir; Merck & Co. Inc.), or Vosevi (sofosbuvir, velpatasvir, and voxilaprevir; Gilead Sciences Inc.) to...
by TractManager | Aug 28, 2019 | Emerging Technology Report
The Barostim neo System is an implantable neuromodulation device designed to improve cardiac function by delivering electrical stimulation to baroreceptors in the wall of the carotid artery. The system is designed to take advantage of the body’s natural baroreflex...
by TractManager | Aug 28, 2019 | News
On August 27, 2019, the Food and Drug Administration (FDA) approved a new drug application (NDA) for Nourianz (istradefylline; Kyowa Kirin Inc.), an oral selective adenosine A2A receptor antagonist for use as an add-on treatment to levodopa/carbidopa in adult patients...
by TractManager | Aug 28, 2019 | Emerging Technology Report
The Barostim neo System is an implantable neuromodulation device designed to improve cardiac function by delivering electrical stimulation to baroreceptors in the wall of the carotid artery. The system is designed to take advantage of the body’s natural baroreflex...
Recent Comments